Evidence map›Paper›PMID 30347712›Full record

ArticleInternational journal of molecular sciences2018

Anti-Angiogenic miR-222, miR-195, and miR-21a Plasma Levels in T1DM Are Improved by Metformin Therapy, Thus Elucidating Its Cardioprotective Effect: The MERIT Study.

Fahad W Ahmed, Sherin Bakhashab, Inda T Bastaman, Rachel E Crossland, Michael Glanville, Jolanta U Weaver

Open access · goldAbstract readClinical Study
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Micro-RNA Implications in Type-1 Diabetes Mellitus: A Review of Literature.International journal of molecular sciences · 2021
    Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Fahad W AhmedDepartment of Diabetes, Queen Elizabeth Hospital, Gateshead, Newcastle Upon Tyne NE9 6SH, UK. nfahadahmed@gmail.com.
Sherin BakhashabInstitute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne NE2 4HH, UK. sbakhashab@kau.edu.sa.ORCID 0000-0003-1580-0409
Inda T BastamanDepartment of Diabetes, Queen Elizabeth Hospital, Gateshead, Newcastle Upon Tyne NE9 6SH, UK. itashab@gmail.com.
Rachel E CrosslandInstitute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne NE2 4HH, UK. rachel.crossland@newcastle.ac.uk.ORCID 0000-0001-6138-160X
Michael GlanvilleInstitute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne NE2 4HH, UK. michael.glanville@newcastle.ac.uk.
Jolanta U WeaverDepartment of Diabetes, Queen Elizabeth Hospital, Gateshead, Newcastle Upon Tyne NE9 6SH, UK. Jolanta.Weaver@newcastle.ac.uk.
Newcastle University · GBKing Abdulaziz University · SAQueen Elizabeth Hospital · GBRoyal Sussex County Hospital · GBUniversity of Indonesia · ID

Funding

Diabetes Research Fund from Queen Elizabeth Hospital, Gateshead BH112851 EPCDiabetes Research & Wellness Foundation open funding 2011
6 · The paper itself

Abstract

Type 1 diabetes (T1DM) is associated with increased cardiovascular disease (CVD) and reduced life expectancy. We thus hypothesized that anti-angiogenic miRs are increased in T1DM, and the cardioprotective effect of metformin is mediated via reducing those miRs. In an open label, case-controlled study, 23 T1DM patients without CVD were treated with metformin for eight weeks (TG), matched with nine T1DM patients on standard treatment (SG) and 23 controls (CG). Plasma miR-222, miR-195, miR-21a and miR-126 were assayed by real-time RT-qPCR. The results were correlated with: endothelial function (RHI), circulating endothelial progenitor cells (cEPCs) (vascular repair marker, CD45

Indexed as

AdultBiomarkersCase-Control StudiesDiabetes Mellitus, Type 1Diabetic AngiopathiesEndothelium, VascularFemaleHumansHypoglycemic AgentsMaleMetforminMicroRNAsMiddle AgedBiomarkersHypoglycemic AgentsMetforminMicroRNAsanti-angiogenicmetforminmiRsT1DM

Identifiers

PMID30347712
PMCPMC6214022
OpenAlexW2897361250

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.